Yongqiang Deng, therefore sought to identify mutations that inhibited Vps74's association with Sac1 without affecting its interactions with other proteins or with PtdIns4P.
Cai et al. determined the crystal structure of the complex formed between Vps74 and the N-terminal portion of Sac1, which contains both the phosphatase's catalytic domain and an additional, well-conserved, N-terminal subdomain (1). The researchers discovered that Vps74 interacts with the N-terminal subdomain of Sac1 and identifi ed point mutations in Vps74 that specifi cally disrupted this interaction. Yeast expressing this Vps74 mutant showed increased PtdIns4P levels at the medial Golgi, supporting the idea that Vps74 acts as a membrane receptor for Sac1. Moreover, the mutant yeast cells were less able to retain the mannosyltransferase Kre2 in the medial Golgi; the enzyme was delivered to the vacuole lumen instead. "So the disorganization that arises from the spread of PtdIns4P has a functional consequence," says Burd. One possibility is that, when PtdIns4P turnover is inhibited, Vps74 gets trapped on the medial Golgi membrane and can't be recycled to the TGN to participate in retrograde transport and enzyme retention.
"Our work highlights how phosphoinositide signaling is restricted to precise membrane compartments in order to maintain their identity," says Burd. PtdIns4P is generated at the TGN, where it recruits the effector protein Vps74 to spur the formation of retrograde transport vesicles. Vps74 and PtdIns4P are incorporated into these vesicles and delivered to earlier Golgi compartments, whereupon Vps74 recruits Sac1 to hydrolyze the phospholipid and terminate the signaling pathway.
Other membrane receptors may recruit Sac1 to different organelles to promote PtdIns4P turnover, and similar mechanisms may target other Sac1 family phosphatases. Mutations in the N-terminal subdomain of Sac3-corresponding to the region of Sac1 that interacts with Vps74-cause CharcotMarie-Tooth disease and amyotrophic lateral sclerosis (5, 6) . "This provides a precedent for thinking about how these mutations cause disease," says Burd. "Sac3 might interact with membrane receptors that direct it to dephosphorylate its substrate phosphoinositide at specifi c organelles."
Burd and colleagues now want to further explore the importance of restricting PtdIns4P to the TGN and to investigate how Sac1 and Vps74 regulate sphingolipid homeostasis, given that mutations in either protein alter the sphingolipid content of Golgi membranes. 
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